论文部分内容阅读
[目的]探讨胃肠安联合肠道活菌制剂治疗感染后肠易激综合征腹泻型的临床疗效。[方法]将76例感染后肠易激综合征腹泻型患者,随机分为2组,每组各38例。治疗组口服胃肠安丸0.1g,3次/d;复方嗜酸乳杆菌片1g,3次/d;马来酸曲美布汀片0.2g,3次/d。对照组口服马来酸曲美布汀片0.2g,3次/d。在连续治疗第2周和第4周对患者大便次数和临床症状进行疗效评估,并观察不良反应。[结果]治疗第2周和第4周2组的临床疗效比较,差异均有统计学意义(P<0.05)。[结论]胃肠安丸联合肠道活菌制剂治疗感染后肠易激综合征腹泻型疗效显著,值得临床推广。
[Objective] To investigate the clinical efficacy of combination of gastrointestinal safety combined with enteric bacteria in treating diarrhea of irritable bowel syndrome after infection. [Methods] Sixty-seven patients with irritable bowel syndrome (IBS) diarrhea were randomly divided into two groups (38 in each group). The treatment group was orally administered with 0.1g of gastrointestinal safety pill, 3 times / d; Lactobacillus acidophilus compound tablets 1g, 3 times / d; trimebutine maleate tablets 0.2g, 3 times / d. The control group oral trimebutine maleate tablets 0.2g, 3 times / d. Patients in the second week and the fourth week of continuous treatment of stool frequency and clinical symptoms were evaluated, and observed adverse reactions. [Results] The clinical curative effect of the 2nd and 4th week in treatment group 2 was statistically significant (P <0.05). [Conclusion] The combination of Weichang’an Pill and intestinal viable bacteria in the treatment of post-infection irritable bowel syndrome diarrhea has significant curative effect and is worthy of clinical promotion.